Vivani Medical (NASDAQ:VANI) Director Buys $1,999,999.26 in Stock

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams bought 1,587,301 shares of Vivani Medical stock in a transaction dated Monday, June 15th. The stock was acquired at an average price of $1.26 per share, with a total value of $1,999,999.26. Following the completion of the transaction, the director directly owned 36,119,086 shares of the company’s stock, valued at approximately $45,510,048.36. The trade was a 4.60% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

Gregg Williams also recently made the following trade(s):

• On Friday, May 15th, Gregg Williams purchased 1,587,301 shares of Vivani Medical stock. The shares were acquired at an average price of $1.26 per share, for a total transaction of $1,999,999.26.
• On Wednesday, April 15th, Gregg Williams acquired 1,587,301 shares of Vivani Medical stock. The shares were acquired at an average cost of $1.26 per share, with a total value of $1,999,999.26.

Vivani Medical Trading Up 2.7%

VANI stock opened at $1.13 on Tuesday. The firm has a 50-day moving average of $1.21 and a two-hundred day moving average of $1.26. Vivani Medical, Inc. has a 12 month low of $0.92 and a 12 month high of $1.92. The company has a market cap of $97.45 million, a price-to-earnings ratio of -2.82 and a beta of 2.31.

Vivani Medical (NASDAQ:VANI) last issued its earnings results on Wednesday, May 13th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). As a group, equities analysts forecast that Vivani Medical, Inc. will post -0.3 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Tudor Investment Corp ET AL purchased a new stake in Vivani Medical during the 4th quarter worth about $1,127,000. Marshall Wace LLP purchased a new position in shares of Vivani Medical in the 4th quarter valued at about $174,000. Geode Capital Management LLC grew its position in shares of Vivani Medical by 29.6% during the fourth quarter. Geode Capital Management LLC now owns 461,652 shares of the company’s stock worth $568,000 after buying an additional 105,398 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Vivani Medical by 118.4% during the fourth quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock worth $121,000 after buying an additional 53,127 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Vivani Medical during the fourth quarter worth approximately $60,000. 6.78% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have commented on VANI. HC Wainwright decreased their price target on Vivani Medical from $4.00 to $3.50 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vivani Medical in a research note on Tuesday, June 9th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $3.50.

About Vivani Medical

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.